Neuphoria Therapeutics Inc. (NEUP)
$3.24-4.42%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $18M
- Beta
- 0.75
- P/E (TTM)
- -0.45
- Short % float
- 0.48%
- Days to cover
- 1.6
- SI change
- -19.0%
- 1W
- -5.26%
- 1M
- -14.29%
- vs SPY 1W
- -5.12%
- vs SPY 1M
- -16.79%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 4
- GROWTH
- 16
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-46.2%
REV YoY-
ROE-19.9%
EPS YoY-
ROA-64.6%
GROSS44
OP-1188
NET-1578
[VALUATION]
P/E TTM-0.45
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B0.71
P/FCF-
EV/EBITDA0.18
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.14
ALTMAN Z-
CURR RATIO27.85
ND/EBITDA-
BETA0.75
NET INCOME (TTM) < 0
Company news
FAQ
- What is LOPJLB’s current signal on NEUP?
- LOPJLB’s latest quantitative signal on Neuphoria Therapeutics Inc. (NEUP) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is NEUP in?
- Neuphoria Therapeutics Inc. (NEUP) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Neuphoria Therapeutics Inc. (NEUP) do?
- Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.